ECT2 amplification and overexpression as a new prognostic biomarker for early-stage lung adenocarcinoma.
Bottom Line: To examine gene abnormalities, 83 cases of various types of lung carcinoma were examined by quantitative real-time genomic PCR and immunohistochemistry.These results were verified using another set of early-stage adenocarcinomas resected at another hospital.Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.
Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Using the 83 cases, IHC for ECT2, EIF5A2, PIK3CA, and TNFSF10 was carried out. Although faint staining was detected in the cytoplasm of the tumor cells, nuclei were mainly stained by antibody against ECT2 (Fig. 2a). For other genes, the cytoplasm or nuclear membrane was stained. The results showed a slight correlation with those of qPCR. The correlation coefficients were: r = 0.36 for ECT2; r = 0.07 for EIF5A2; r = 0.13 for PIK3CA; and r = 0.14 for TNFSF10. Of these four genes, ECT2 was correlated most closely with the qPCR value.
Affiliation: Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan.